Sign in3 stories
The divestiture delivered $7.7 million at closing, with the company's press release citing an $8 million closing figure and up to $3 million more in potential milestone payments.
SEC filing
The company said fresh credit and divestiture proceeds fund it through NXT-41x's expected clearance and 2028 launch year, alongside second-quarter results.
SEC filing
The divestiture is meant to fund Elutia's push toward its NXT-41x biomatrix, which the company expects to clear regulatory review and launch commercially in 2027.
SEC filing